Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, biomarkers, and other cancer treatments, will be highlighted at the American ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

An integrated strategy for the prevention, support and treatment of prostate cancer was launched today. The plan, which was ...

A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...

February 4 is observed as World Cancer Day. And one of the challenges men face is prostate cancer. Statistics show that, globally, approximately 1 in 8 men will be diagnosed with prostate cancer at ...

A mother of two with many dreams, she discovered a lump in her breast. A subsequent diagnosis confirmed her worst fear: ...

A physician, Dr. Sam Adegboye, has debunked the claim that frequent sexual activity reduces the risk of prostate cancer in men. Adegboye is the Assistant Chief Medical Officer and General Practitioner ...

By Temitope PonleDr Sam Adegboye, a Physician, has debunked the claim that frequent sexual activity reduces the risk of prostate cancer in men.Adegboye is the Assistant Chief Medical Officer and ...

When prostate cancer metastasizes, spreads outside of the prostate itself, it typically affects the structures in its immediate vicinity. Structures near the prostate likely to be involved include ...

At the New Mexico Cancer Center in Albuquerque, groundbreaking treatments and compassionate care are helping change the lives ...

Ear cancer is when abnormal cells in the ear start to grow and divide in an uncontrolled way. Most of these cancers start in the skin of the outer ear. Cancers that develop inside the ear, known as ...